Physician profile
Christopher G Webber
NPI 1629350301
$5,573.60
in general payments reported to CMS, 2019-2025
25 companies · $2,587 in 2025
The $2,587 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $126 · 2023: $1,252 · 2024: $1,609 · 2025: $2,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,210 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,210.00 |
| Education | $237.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,167.31 | 2022-2025 | |
| Dermavant Sciences, INC. | $682.03 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $466.29 | 2023-2025 | Tremfya, Remicade, Simponi Aria |
| Lilly USA, LLC | $439.89 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $420.74 | 2022-2025 | Sotyktu |
| Pfizer INC. | $384.85 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $260.38 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $255.07 | 2022-2025 | |
| Ucb, INC. | $246.22 | 2023-2025 | Bimzelx |
| Leo Pharma INC. | $235.42 | 2024-2025 | Adbry, Anzupgo, Spevigo |
| Incyte Corporation | $171.90 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $144.97 | 2023-2025 | |
| Organon LLC | $131.44 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $131.26 | 2023-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $93.60 | 2023-2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $77.89 | 2025 | |
| Almirall LLC | $65.07 | 2025 | Seysara, Klisyri |
| Botanix Sb INC | $54.63 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $38.50 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.11 | 2023 | Arazlo |
| Verrica Pharmaceuticals INC. | $20.84 | 2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.73 | 2025 | Spevigo |
| Biofrontera INC. | $15.62 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Journey Medical Corporation | $14.95 | 2023 | |
| Amgen INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Webber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.